Evaluation the clinical utility of KRAS mutation assay using tumor samples (tissue, cytology) and blood samples in patients with pancreatic cancer.
Not Applicable
Recruiting
- Conditions
- pancreatic cancer
- Registration Number
- JPRN-UMIN000052237
- Lead Sponsor
- St.Marianna University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients whose participation in this study is decided inappropriate by the principal investigator or subinvestigator. 2. Patients who are strongly suspected to have a specific type of pancreatic cancer based on tumor markers (e.g., IPMC (intraductal papillary mucinous carcinoma), NEN (neuroendocrine neoplasm)).
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Success rate of KRAS mutation assay, including tumor samples of tissue and cytology and blood samples
- Secondary Outcome Measures
Name Time Method